scholarly journals Rhabdomyolysis in a Healthy Peripheral Blood Stem Cell Donor following Mobilization with Filgrastim

2009 ◽  
Vol 36 (2) ◽  
pp. 135-137 ◽  
Author(s):  
Sibel Hacioglu ◽  
Fevzi Altuntas ◽  
Leylagul Kaynar ◽  
Ismail Sari ◽  
Turkan Patiroglu ◽  
...  
Keyword(s):  
Stem Cell ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Cell Donor

scholarly journals Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study

2019 ◽  
Vol 25 (4) ◽  
pp. 699-711 ◽  
Author(s):  
Michael A. Pulsipher ◽  
Brent R. Logan ◽  
Pintip Chitphakdithai ◽  
Deidre M. Kiefer ◽  
Marcie L. Riches ◽  
...  
Keyword(s):  
Stem Cell ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Experience Report ◽  
Blood Stem Cell ◽  
Safety Study ◽  
Cell Donor ◽  
Donor Safety ◽  
Related Donor

scholarly journals Janus kinase 2 V617F mutation in an unrelated peripheral blood stem cell donor

2019 ◽  
Vol 31 (1) ◽  
pp. 60
Author(s):  
Tso-Fu Wang ◽  
Shang-Hsien Yang ◽  
Hsiang-Lin Wan ◽  
Ming-Hui Gu
Keyword(s):  
Stem Cell ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Janus Kinase ◽  
Janus Kinase 2 ◽  
Cell Donor ◽  
V617f Mutation

High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma

2001 ◽  
Vol 40 (06) ◽  
pp. 215-220 ◽  
Author(s):  
S. Bielack ◽  
S. Flege ◽  
J. Eckardt ◽  
J. Sciuk ◽  
H. Jürgens ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
High Activity ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
High Dose ◽  
External Radiotherapy ◽  
Primary Tumor Site ◽  
Hematopoietic Stem

Summary Purpose: Despite highly efficacious chemotherapy, patients with osteosarcomas still have a poor prognosis if adequate surgical control cannot be obtained. These patients may benefit from therapy with radiolabeled phosphonates. Patients and Methods: Six patients (three male, three female; seven to 41 years) with unresectable primary osteosarcoma (n = 3) or unresectable recurrent sites of osteosarcomas (n = 3) were treated with high-activity of Sm-153-EDTMP (150 MBq/kg BW). In all patients autologous peripheral blood stem cells had been collected before Sm-153-EDTMP therapy. Results: No immediate adverse reactions were observed in the patients. In one patient bone pain increased during the first 48 hrs after therapy. Three patients received pain relief. Autologous peripheral blood stem cell reinfusion was performed on day +12 to +27 in all patients to overcome potentially irreversible damage to the hematopoietic stem cells. In three patient external radiotherapy of the primary tumor site was performed after Sm-153-EDTMP therapy and in two of them polychemotherapy was continued. Thirty-six months later one of these patients is still free of progression. Two further patients are still alive. However, they have developed new metastases. The three patients who had no accompanying external radiotherapy, all died of disease progression five to 20 months after therapy. Conclusion: These preliminary results show that high-dose Sm-153-EDTMP therapy is feasible and warrants further evaluation of efficacy. The combination with external radiation and polychemotherapy seems to be most promising. Although osteosarcoma is believed to be relatively radioresistant, the total focal dose achieved may delay local progression or even achieve permanent local tumor control in patients with surgically inaccessible primary or relapsing tumors.

Comparing peripheral blood stem cell collection using the COBE Spectra, Haemonetics MCS+, and Baxter Amicus

2012 ◽  
Vol 47 (3) ◽  
pp. 345-350 ◽  
Author(s):  
Fei-yi Wu ◽  
Kee Khiang Heng ◽  
Rohani Binte Salleh ◽  
Teck Guan Soh ◽  
Jing Jing Lee ◽  
...  
Keyword(s):  
Stem Cell ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Stem Cell Collection
Sign in / Sign up

Export Citation Format

Share Document